Correction: Clinical performance of a dual-target SARS CoV-2 antibody assay using sera from Ghana - Summary - MDSpire

Correction: Clinical performance of a dual-target SARS CoV-2 antibody assay using sera from Ghana

  • By

  • Prince Jonathan Pappoe-Ashong

  • Julius Abraham A. Mingle

  • Derrick Tetteh

  • Martha S. Dsane-Lamptey

  • Joseph A. Oliver-Commey

  • Peter Puplampu

  • Christian Jassoy

  • June 17, 2026

  • 0 min

Share

Objective:

Correction of the author's name in the original article.

Key Findings:
  • The author's name was incorrectly written as Peter Puplumpu.
  • The correct name is Peter Puplampu.
Interpretation:

Conclusion:

This erratum clarifies the authorship of the original publication.

Sources:

Original Source(s)

Correction: Clinical performance of a dual-target SARS CoV-2 antibody assay using sera from Ghana

  • by Prince Jonathan Pappoe-Ashong, Julius Abraham A. Mingle, Derrick Tetteh, Martha S. Dsane-Lamptey, Joseph A. Oliver-Commey, Peter Puplampu, Christian Jassoy

  • June 17, 2026

Related Content

Harnessing Participatory Surveillance Cohorts and Proxy Indicators to Dynamically Track Epidemic Trends and Undiagnosed COVID-19 Infections in Singapore: Longitudinal Observational Study

ACOG Releases 2026 Maternal Immunization Schedule

Thirteen other organizations endorsed guidance that extends across pregnancy, postpartum care, and lactation.

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates